Targeting the hepatocyte growth factor-cMET axis in cancer therapy
about
Recent updates of precision therapy for gastric cancer: Towards optimal tailored managementRecent developments in receptor tyrosine kinases targeted anticancer therapyMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerIrreversible EGFR-TKIs: dreaming perfectionMET inhibitors for treatment of advanced hepatocellular carcinoma: A reviewBeyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancersProfile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to dateThe oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitorHepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic TargetHepatocyte growth factor is a prognostic marker in patients with colorectal cancer: a meta-analysis.MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.Clinical update on cancer: molecular oncology of head and neck cancerYhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells89Zr-Onartuzumab PET imaging of c-MET receptor dynamics.c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancerHGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells.HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancerSulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal modelcMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast CancerMulti-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas.Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.Functional consequence of the MET-T1010I polymorphism in breast cancerPET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor.Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer modelThe EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model.Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma.The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.Isothiocyanatostilbenes as novel c-Met inhibitors.Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis.Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.Gelsolin-mediated activation of PI3K/Akt pathway is crucial for hepatocyte growth factor-induced cell scattering in gastric carcinoma.c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
P2860
Q26746246-56F0B023-36F0-47DF-A6C9-86B790CCD111Q26751331-B1BA4BF0-FAD3-43CC-881B-ADB710924E3AQ26772969-4072BEF5-E4E9-41D5-A137-848140EB44B1Q26866186-0FC8E33A-5F02-443F-896E-D1689086C697Q27014423-58DF7C04-526D-40C6-BED1-4F57A76E734DQ28066550-D6E96A15-7902-4FEB-86D7-D7E369948BD7Q28071589-E53AA175-A067-4745-A375-A9BF42194227Q28821187-9AC652BF-7061-4A3C-8D24-F3BC98FBF6A8Q33565746-A0A626C9-0981-454A-8C97-FE512B6D352EQ33618725-EF260CA6-329B-419F-9642-9FA0C73810F4Q33688421-B32F53DF-3B29-4E7F-93D8-05796E8DB100Q33695197-06D37E98-02D0-4173-B809-A3EC8C25E402Q33823715-981DBCF7-1AD5-4330-BC42-4EABA60D63BEQ33841490-0D34D863-F91C-421A-A0EC-E9A8326352B8Q33886974-702D566C-55CB-43BE-AE1F-CA494E0819BFQ33917507-BFC5B50A-9884-43D2-BC98-6F7733EA256FQ33984904-2C91478A-BD67-4074-A363-19A46EA6C382Q34104074-2CB141EB-EA5E-464D-9218-DC54C48D6AECQ34104125-6DF84C7F-E7B2-4057-9CFD-05123E634D89Q34438708-65C25065-8241-4ABB-B093-5F0B099CE24BQ35160825-7AFF83E5-B26E-499F-B8BA-B8BC4EC72DACQ35222611-282D3538-F72E-4387-93CE-694F7D3D95D4Q35238436-3A5EAECD-76C2-4E83-AEE4-0AA118C462E0Q35550045-776E954F-4D9E-44CE-A8A6-5265297CD326Q35562996-A81262AF-425B-4293-819D-160D06F3C0DCQ35605388-BD4ABC58-3B85-4659-B88A-2568C59154D4Q35636713-A7E40E3C-E4BC-40D2-A005-96A7BE95C5E5Q35740444-FBD56955-09FA-4880-A443-5E7F46E5240FQ35786233-CEF442BA-8C78-4B98-B82E-3111C264CF6FQ35955290-A8F5C9C5-4453-4160-8D84-367088CDCBBEQ35982925-6E3F8B44-C321-4AE6-94F1-0683DC04EBA0Q35999644-5C4B3AC5-8009-4D3D-B811-1124A2CCCA13Q36307708-F05F480B-9556-4357-B023-498D4FF70071Q36544653-430688E4-CE1B-413E-AEE8-BAA5736F82A7Q36562316-35BF2549-72EA-4D5F-8C65-A849C87A4690Q36766188-65377194-0A31-4A0E-BF6F-AAC91525DB7CQ36953116-FF8D1892-630F-4D21-997E-5839953A8003Q37236103-699EE5C7-4974-4ABD-A803-1E5F44903218Q37295357-9B97F733-6EA4-4DDB-8718-8B1E61D88EB5Q37472110-C75943B3-8959-4123-9F28-17E424E7F06D
P2860
Targeting the hepatocyte growth factor-cMET axis in cancer therapy
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Targeting the hepatocyte growth factor-cMET axis in cancer therapy
@ast
Targeting the hepatocyte growth factor-cMET axis in cancer therapy
@en
Targeting the hepatocyte growth factor-cMET axis in cancer therapy
@nl
type
label
Targeting the hepatocyte growth factor-cMET axis in cancer therapy
@ast
Targeting the hepatocyte growth factor-cMET axis in cancer therapy
@en
Targeting the hepatocyte growth factor-cMET axis in cancer therapy
@nl
prefLabel
Targeting the hepatocyte growth factor-cMET axis in cancer therapy
@ast
Targeting the hepatocyte growth factor-cMET axis in cancer therapy
@en
Targeting the hepatocyte growth factor-cMET axis in cancer therapy
@nl
P2860
P3181
P356
P1476
Targeting the hepatocyte growth factor-cMET axis in cancer therapy
@en
P2093
Ana M Gonzalez-Angulo
Gordon B Mills
P2860
P304
P3181
P356
10.1200/JCO.2011.40.3774
P407
P577
2012-09-10T00:00:00Z